Enterprise’s Phase II trial of ETD001 meets primary endpoint in pwCF

Enterprise Therapeutics has announced that its Phase II clinical trial of ETD001, an investigational inhaled ENaC blocker in pwCF, has met its primary efficacy outcome. The Phase II study was conducted in France, Germany, Italy and the UK in pwCF. ETD001 is designed to enhance lung function by supporting mucus clearance. Credit: Jo Panuwat D / Shutterstock.com. Enterprise Therapeutics (Enterprise) has announced that its Phase II clinical trial of ETD001, an investigational inhaled epithelial sodium channel (ENaC) blocker in people with cystic fibrosis (pwCF), has met its primary efficacy outcome. The study is designed to assess the efficacy, pharmacokinetics, safety…

Source: Clinical Trials Arena